{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T10:05:12Z","timestamp":1760954712194},"reference-count":16,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2005,2,22]],"date-time":"2005-02-22T00:00:00Z","timestamp":1109030400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatric Anesthesia"],"published-print":{"date-parts":[[2005,3]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:bold>Background<\/jats:bold> :\u2002Postoperative bleeding and blood product requirements can be substantial in children undergoing open\u2010heart surgery, and reexploration is required in 1% of cases. Recombinant activated factor VII (rFVIIa, NovoSeven<jats:sup>\u00ae<\/jats:sup>, NovoNordisk, Denmark) is a hemostatic agent approved for the treatment of hemophilic patients with inhibitors to factor VIII or factor IX. It has also been used with success in other conditions. We present our experience with rFVIIa treatment for uncontrolled bleeding after open\u2010heart surgery in five pediatric patients.<\/jats:p><jats:p><jats:bold>Methods<\/jats:bold> :\u2002The study group consisted of five patients after open\u2010heart surgery with excessive blood loss. The patients were treated with rFVIIa after failure of conventional treatment to control the bleeding. Blood loss, blood product consumption, and coagulation test results were recorded before and after rFVIIa administration.<\/jats:p><jats:p><jats:bold>Results<\/jats:bold> :\u2002In all cases, blood loss decreased considerably after rFVIIa administration (mean 7.8\u2003ml\u00b7kg<jats:sup>\u22121<\/jats:sup>\u00b7h<jats:sup>\u22121<\/jats:sup>), almost eliminating the need for additional blood products, and the prolonged prothrombin time normalized. In two patients with thrombocytopathy, rFVIIa helped to discriminate surgical bleeding from bleeding caused by a defect in hemostasis. No side effects of rFVIIa treatment were noted.<\/jats:p><jats:p><jats:bold>Conclusions<\/jats:bold> :\u2002These cases support the impression that RFVIIa is efficient and safe in correcting hemostasis in children after cardiopulmonary bypass when other means fail. However, the data are still limited, and more extensive research is needed.<\/jats:p>","DOI":"10.1111\/j.1460-9592.2005.01429.x","type":"journal-article","created":{"date-parts":[[2005,2,22]],"date-time":"2005-02-22T17:34:01Z","timestamp":1109093641000},"page":"235-240","source":"Crossref","is-referenced-by-count":54,"title":["Recombinant factor VIIa (NovoSeven<sup>\u00ae<\/sup>) as a hemostatic agent after surgery for congenital heart disease"],"prefix":"10.1111","volume":"15","author":[{"given":"YARON","family":"RAZON","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"ELDAD","family":"EREZ","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"BERNARDO","family":"VIDNE","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"EINAT","family":"BIRK","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JACOB","family":"KATZ","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"HANNA","family":"TAMARI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"OVADIA","family":"DAGAN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2005,2,22]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1182\/blood.V77.5.930.930","article-title":"Comparison of the hemostatic effect of fresh whole blood, and components after open heart surgery in children","volume":"77","author":"Manno CS","year":"1991","journal-title":"Blood"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1213\/00000539-199907000-00011"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/1010-7940(94)90128-7"},{"key":"e_1_2_5_5_2","first-page":"397","volume-title":"Pediatric Cardiac Intensive Care","author":"Grayck EN","year":"1994"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0003-4975(01)03218-0"},{"issue":"12","key":"e_1_2_5_7_2","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0037-1963(01)90147-7","article-title":"Recombinant factor VIIa (NovoSeven\u00ae) as a hemostatic agent","volume":"38","author":"Hedner U.","year":"2001","journal-title":"Semin Hematol"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-002-1467-3"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000539-200108000-00009"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1997.4463256.x"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-002-1471-7"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001721-200004001-00023"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1097\/00130478-200301000-00009"},{"issue":"4","key":"e_1_2_5_14_2","first-page":"21","article-title":"Use of recombinant factor VIIa (NovoSeven\u00ae) in patients with Glanzmann thrombasthenia","volume":"38","author":"Poon MC","year":"2001","journal-title":"Semin Hematol"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(97)70013-1"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2002.34164"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000539-200205000-00070"}],"container-title":["Pediatric Anesthesia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1460-9592.2005.01429.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1460-9592.2005.01429.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T23:01:53Z","timestamp":1696892513000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1460-9592.2005.01429.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,2,22]]},"references-count":16,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,3]]}},"alternative-id":["10.1111\/j.1460-9592.2005.01429.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1460-9592.2005.01429.x","archive":["Portico"],"relation":{},"ISSN":["1155-5645","1460-9592"],"issn-type":[{"value":"1155-5645","type":"print"},{"value":"1460-9592","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,2,22]]}}}